PeptideDeepDiveSemaglutide: FDA & EU Approval, Safety & Evidence
Semaglutide is the active ingredient in approved GLP-1 medicines including Ozempic, Rybelsus and Wegovy. This guide explains the evidence, current US and EU approvals, safety warnings, and why approved medicines are not interchangeable with compounded or research-labelled products.
Semaglutide is an active ingredient used in several prescription medicines. Approval is product- and indication-specific.
In this semaglutide guide
What is semaglutide?
Semaglutide is a modified peptide that acts like GLP-1, a natural gut hormone. In other words, it belongs to a group of medicines called GLP-1 receptor agonists.
When blood sugar is high, semaglutide can help the body release insulin. It may also reduce glucagon, a hormone that raises blood sugar. In addition, it can slow stomach emptying and affect appetite. However, the active ingredient is only one part of a medicine. Each approved product has a set formula, strength, delivery method, label and quality process.
Therefore, “semaglutide” can describe an active ingredient, while Ozempic, Rybelsus and Wegovy describe regulated products. That distinction matters. A vial sold online with a semaglutide label does not inherit the approvals of those medicines. For the wider drug-class picture, see our GLP-1 medicines comparison.
Which semaglutide products are approved in the US and Europe?
The FDA and European regulators assess named medicines. Therefore, they do not approve semaglutide as a broad, free-standing category.
| Product | Form | Core regulatory role | US / Europe snapshot |
|---|---|---|---|
| Ozempic | Injection | Type 2 diabetes, with added labelled risk-reduction uses in defined groups | Authorised in US and EU |
| Rybelsus | Tablet | Type 2 diabetes; current labels must be checked for region-specific claims | Authorised in US and EU |
| Wegovy | Injection | Weight management; additional labelled uses vary by regulator and date | Authorised in US and EU |
| Wegovy tablets | Tablet | Oral weight-management formulation for adults | Authorised in US and EU |
Europe note: the EMA’s current Wegovy product information now includes tablets for adults as well as the injectable form. The tablet extension followed a positive CHMP opinion in May 2026 and was incorporated into the EU product information later in 2026. National availability and reimbursement can still differ.
Why the European distinction matters
In Europe, the European Medicines Agency reviews the scientific evidence for many medicines. Next, the European Commission decides whether to grant an EU-wide marketing authorisation. Even so, access can vary because each country makes its own pricing, funding and supply decisions.
For example, Ireland, Germany, France and Spain can share an EU authorisation while applying different reimbursement or prescribing rules. As a result, “approved in Europe” does not always mean “available on the same terms in every European country.”
How does semaglutide work as a GLP-1 medicine?
Semaglutide binds to and activates the GLP-1 receptor. Its design also extends its action compared with native GLP-1.
After the receptor becomes active, several linked effects can occur. For example, insulin release can rise when blood sugar is high, while glucagon release can fall. Stomach emptying may also slow, especially early in treatment. In addition, GLP-1 signals reach brain areas linked with appetite.
These biological effects help explain the approved uses. However, a mechanism is not proof that a drug will help every person. Clinical trials must still show benefits and risks for a defined population, product and outcome.
How is semaglutide trialled and monitored?
An approved semaglutide medicine moves through a formal drug-development process. Regulators then continue to monitor it after approval.
Clinical evidence before approval
First, drug developers study the molecule in the laboratory and in early models. Next, human trials test how the drug acts, whether it works and which risks appear. Regulators then review the full application, not only a headline result. They also check production standards and the proposed label.
Semaglutide programmes include large trials in diabetes, weight management and cardiovascular outcomes. Later applications also supported added indications. Importantly, each claim has its own evidence package.
Safety monitoring after approval
Approval does not end safety work. In the US, the FDA collects reports about side effects, medicine errors and product quality. In Europe, national authorities, the EMA and its PRAC safety committee share this work.
However, an individual report does not prove that a medicine caused an event. Reports may be incomplete or repeated. Therefore, regulators compare report patterns with trials, real-world studies and other evidence before they change advice or labels.
Semaglutide approval timeline
This timeline shows why semaglutide sits in a different evidence and regulatory category from unapproved research peptides.
Ozempic receives its first US approval
The FDA approved injectable Ozempic for adults with type 2 diabetes. This approval created the first US semaglutide medicine.
Rybelsus becomes the first oral GLP-1 medicine
The FDA approved Rybelsus tablets for type 2 diabetes. It was the first orally administered GLP-1 receptor agonist product.
Wegovy is approved for chronic weight management
The FDA approved injectable Wegovy for defined adults with obesity or overweight. The EU later authorised Wegovy through its central system.
Wegovy gains a US cardiovascular risk-reduction indication
The FDA added an indication to reduce major cardiovascular events in adults with established cardiovascular disease and obesity or overweight.
Kidney and MASH indications expand the US labels
In January, the FDA added a kidney and heart-risk indication to Ozempic for adults with type 2 diabetes and chronic kidney disease. Then, in August, it approved Wegovy injection for certain adults with MASH without cirrhosis and moderate to advanced liver scarring. The agency used its accelerated approval pathway for that use.
Oral Wegovy is approved in the US and authorised in the EU
FDA approved Wegovy tablets in December 2025. In Europe, the CHMP recommended the oral formulation in May 2026 and the current EU Wegovy product information now includes tablets for adults. Availability and reimbursement still vary by country.
Semaglutide safety and monitoring
An approved medicine can have strong evidence and still carry meaningful risks. Approval means regulators judged that benefits outweigh known risks for the approved use and population.
US semaglutide labels carry a boxed warning about thyroid C-cell tumours seen in rodents. In addition, the labels say people should not use these medicines if they or their family have had medullary thyroid carcinoma, a type of thyroid cancer. The same restriction applies to people with Multiple Endocrine Neoplasia syndrome type 2.
Common and serious label issues
For example, nausea, vomiting, diarrhoea and constipation are common in semaglutide trials. Labels also describe less common but important risks. These include pancreas or gallbladder problems, kidney injury linked with fluid loss and low blood sugar with some medicine combinations. In addition, labels cover diabetic eye problems and the risk of stomach contents entering the airway during anaesthesia or deep sedation.
In Europe, the EMA safety committee also concluded that NAION, an eye condition that can cause vision loss, is a very rare side effect of semaglutide medicines. Consequently, sudden vision loss needs urgent medical attention.
What monitoring means in practice
Therefore, a prescriber can review the approved use, medical history, other medicines and label warnings. They can also explain which symptoms need quick medical care. This guide does not replace that assessment.
Semaglutide vs research-grade peptides
The main difference is not whether both molecules contain amino acids. The key difference is the evidence and regulatory framework around the finished product.
| Question | Approved semaglutide medicine | Product sold as “research-grade” |
|---|---|---|
| Approved patient use? | Yes, for the product’s labelled indications | No approval follows from an RUO label |
| Human evidence? | Regulator-reviewed clinical programme | No medicine-level approval is established by the label |
| Manufacturing? | Defined controls, specifications and inspections | Quality can vary; medicinal GMP status is not assumed |
| Patient instructions? | Official prescribing information and patient leaflet | No regulator-validated patient dose or indication |
| Safety monitoring? | Formal medicine-safety monitoring and label updates | No matching product-specific system is guaranteed |
| Supply route? | Prescription and authorised pharmacy supply | Often sold “not for human consumption” |
In contrast, calling semaglutide a peptide does not place approved Wegovy or Ozempic in the same category as BPC-157, TB-500 or another unapproved research compound. For a fuller comparison, read research-grade vs approved medicines explained. For laboratory-product quality questions, see our peptide purity and COA guide.
Semaglutide vs tirzepatide: what is the high-level difference?
Semaglutide and tirzepatide both appear in approved metabolic medicines. However, they do not use the same receptor mechanism.
Semaglutide
A GLP-1 receptor agonist. Approved products include Ozempic, Rybelsus and Wegovy, each with its own form and label.
Tirzepatide (10mg / 30mg / 60mg)
A dual GIP and GLP-1 receptor agonist. Approved products include Mounjaro and Zepbound for specific uses.
Importantly, trial groups, outcomes, doses and product labels differ. For that reason, percentages from separate trials cannot prove that one medicine is best for an individual. See the separate tirzepatide mechanism and regulatory guide for more context.
Approved, compounded and “research” semaglutide are not interchangeable
A compounded drug can serve a patient-specific need in limited legal circumstances. However, it is not an FDA-approved copy.
FDA declared the US shortage of semaglutide injections resolved on 21 February 2025. The shortage-based enforcement windows for routine copies subsequently ended. FDA reiterated in April 2026 that section 503A generally restricts regular compounding of products that are essentially copies of commercially available drugs, except in limited patient-specific circumstances.
In 2026, FDA also warned about unapproved GLP-1 products sold with labels such as “for research purposes” or “not for human consumption.” Such wording does not create an approved medicine. In April 2026, FDA additionally proposed excluding semaglutide, tirzepatide and liraglutide from the 503B Bulks List after finding no clinical need for outsourcing facilities to compound them from bulk substances. That proposal is separate from approval of branded medicines.
Check the exact product, route, label and supply chain. An approved active ingredient does not make every compounded, copied or “research” version approved. In Europe, use the EMA product information and the relevant national authority. In the US, use Drugs@FDA and current FDA compounding notices.
Semaglutide FAQ
Is semaglutide FDA-approved?
Yes. FDA-approved semaglutide products include Ozempic, Rybelsus and Wegovy for specific labelled uses. Approval applies to the named product, formulation and indication; it does not make every product sold as semaglutide FDA-approved.
Is semaglutide approved in Europe?
Yes. The European Union has authorised semaglutide medicines including Ozempic, Rybelsus and Wegovy for defined uses. Product forms, indications, reimbursement and availability can differ by country, so check the current EMA information and the relevant national medicines authority.
Is semaglutide a peptide?
Semaglutide is a peptide-based GLP-1 receptor agonist. However, an approved semaglutide medicine is not the same regulatory category as an unapproved product labelled “research-grade” or “research use only.”
How is semaglutide different from research-grade peptides?
Approved semaglutide products have regulator-reviewed evidence, defined manufacturing controls, prescribing information and post-market safety monitoring. A research-grade label does not provide a marketing authorisation, approved indication, validated patient dosing or the same medicine-level oversight.
What is the difference between semaglutide and tirzepatide?
Semaglutide activates the GLP-1 receptor. Tirzepatide activates both GIP and GLP-1 receptors. Both active ingredients appear in approved prescription medicines, but their brands, indications, labels and evidence are not interchangeable.
Does PeptideDeepDive recommend using semaglutide?
No. PeptideDeepDive provides educational information and does not recommend a medicine for an individual. A qualified prescriber should assess benefits, risks, contraindications and monitoring needs.
This article was checked against current FDA and EMA product information, approval records and safety communications. PeptideDeepDive does not claim clinician review unless a named qualified medical reviewer has completed that review.
Primary sources
- US FDA — The Drug Development Process.
- US FDA — Wegovy prescribing information (2026).
- US FDA — Wegovy labeling review noting tablet approval under NDA 218316 (2026).
- European Medicines Agency — Wegovy EPAR.
- European Medicines Agency — Ozempic EPAR.
- European Medicines Agency — Rybelsus EPAR.
- US FDA — Wegovy cardiovascular risk-reduction indication (2024).
- US FDA — Ozempic chronic kidney disease approval letter (2025).
- US FDA — Wegovy MASH indication (2025).
- European Medicines Agency — CHMP opinion on oral Wegovy (2026).
- US FDA — Semaglutide shortage resolution and compounding policy.
- US FDA — Concerns with unapproved GLP-1 products (2026).
- European Medicines Agency — NAION safety review.
Related metabolic research products
Tirzepatide
Dual GIP and GLP-1 research context. This listing is not an authorised Mounjaro or Zepbound medicine.
Retatrutide (5–50mg)
Triple-agonist research context. Retatrutide is not an approved medicine in the US, UK or European Union.
NAD+ (500mg / 1000mg)
Metabolism and cellular-energy research context. This supplier entry is for laboratory research only.
Affiliatevermelding: PeptideDeepDive may earn a commission from supplier links. Product listings are not medical recommendations. Prices reflect supplier data checked on 18 September 2026 and may change; an online research listing should not be confused with an authorised branded medicine.